Sign In
Buy EW
$86.00
-1.66 (-1.89%)
At Close: Jun 03, 2026
Smart Money Going in Senior Health: Key Stocks in Elderly Care
10:50am, Friday, 11'th Jul 2025
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
East West Petroleum Provides Corporate Update
07:00am, Tuesday, 08'th Jul 2025
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide this further corporate update. In the Company's
East West Petroleum Provides Corporate Update
07:00am, Wednesday, 02'nd Jul 2025
Vancouver, British Columbia--(Newsfile Corp. - July 2, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that the Board of directors has approved, subject to shareh
Edwards Lifesciences: With A Heart Beating Strong And Steady
02:11pm, Wednesday, 04'th Jun 2025
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, sho
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
09:55am, Friday, 23'rd May 2025
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
02:30am, Thursday, 22'nd May 2025
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, f
Trade Tracker: Bill Baruch buys Edwards Lifesciences
02:13pm, Monday, 19'th May 2025
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
07:36am, Friday, 16'th May 2025
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
07:05am, Tuesday, 06'th May 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chi
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens
02:42pm, Thursday, 24'th Apr 2025
Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
07:45am, Thursday, 24'th Apr 2025
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Edwards Lifesciences Corporation (EW) Q1 2025 Earnings Call Transcript
09:35pm, Wednesday, 23'rd Apr 2025
Edwards Lifesciences Corporation (NYSE:EW ) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Company Participants Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem -
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
07:00pm, Wednesday, 23'rd Apr 2025
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Stre
Edwards Lifesciences raises 2025 sales forecast after robust quarter
05:43pm, Wednesday, 23'rd Apr 2025
Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat
04:41pm, Wednesday, 23'rd Apr 2025
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales.
